康方生物(09926)：AK112–303达到PFS优效显著阳性结果

智通财经05-31

智通财经APP讯，康方生物(09926)发布公告，该公司自主研发的全球首创双特异性抗体新药依达方®(依沃西注射液，PD-1/VEGF)对比帕博利珠单药一线治疗PD-L1表达阳性(PD-L1TPS≥1%)的局部晚期或转移性非小细胞肺癌(NSCLC)的注册性III期临床试验AK112–303(HARMONi-2)，由独立数据监察委员会(IDMC)进行的预先设定的期中分析显示达到无进展生存期(PFS)的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2439602814?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-05-31 06:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2439602814","market":"hk","top_or_hot":-1,"title":"康方生物(09926)：AK112–303达到PFS优效显著阳性结果","media":"智通财经","content":"<div>\n<p>智通财经APP讯，康方生物(09926)发布公告，该公司自主研发的全球首创双特异性抗体新药依达方®(依沃西注射液，PD-1/VEGF)对比帕博利珠单药一线治疗PD-L1表达阳性(PD-L1TPS≥1%)的局部晚期或转移性非小细胞肺癌(NSCLC)的注册性III期临床试验AK112–303(HARMONi-2)，由独立数据监察委员会(IDMC)进行的预先设定的期中分析显示达到无进展生存期(PFS)的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1128755.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康方生物(09926)：AK112–303达到PFS优效显著阳性结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康方生物(09926)：AK112–303达到PFS优效显著阳性结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-31 06:40 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1128755.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康方生物(09926)发布公告，该公司自主研发的全球首创双特异性抗体新药依达方®(依沃西注射液，PD-1/VEGF)对比帕博利珠单药一线治疗PD-L1表达阳性(PD-L1TPS≥1%)的局部晚期或转移性非小细胞肺癌(NSCLC)的注册性III期临床试验AK112–303(HARMONi-2)，由独立数据监察委员会(IDMC)进行的预先设定的期中分析显示达到无进展生存期(PFS)的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1128755.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1128755.html","article_id":"2439602814","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2439602814","pubTimestamp":1717108816,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，康方生物 发布公告，该公司自主研发的全球首创双特异性抗体新药依达方对比帕博利珠单药一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的注册性III期临床试验AK112–303，由独立数据监察委员会进行的预先设定的期中分析显示达到无进展生存期的主要研究终点。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","PFS":"Provident Financial Services Inc","LU0348783233.USD":"安联东方收入型 CI A Dis美元","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","BK4211":"区域性银行","09926":"康方生物","BK4195":"互助储蓄与抵押信贷金融服务","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1720050803.USD":"安联全方位中国股票基金"},"translate_title":"Akeso Bio (09926): AK112-303 achieved a significant positive result of PFS superiority","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1,"PFS":1},"content_text":"智通财经APP讯，康方生物(09926)发布公告，该公司自主研发的全球首创双特异性抗体新药依达方®(依沃西注射液，PD-1/VEGF)对比帕博利珠单药一线治疗PD-L1表达阳性(PD-L1TPS≥1%)的局部晚期或转移性非小细胞肺癌(NSCLC)的注册性III期临床试验AK112–303(HARMONi-2)，由独立数据监察委员会(IDMC)进行的预先设定的期中分析显示达到无进展生存期(PFS)的主要研究终点。依沃西组的患者，包括PD-L1低表达(TPS1–49%)，PD-L1高表达(TPS≥50%)，以及其他高风险患者，均临床获益显著。试验结果表明：●在意向治疗人群(ITT)中，依沃西组相较于帕博利珠组显著延长了PFS，风险比(HR)显著优于预期。●依沃西成为全球首个且唯一在叁期单药头对头临床研究中证明疗效显著优于帕博利珠的药物。●依沃西组在PD-L1TPS1–49%及PD-L1TPS≥50%人群，PFS获益均非常显著。●依沃西组各个亚组疗效分析均显示强阳性结果，包括鳞癌、非鳞癌，有/无肝转移，有/无脑转移等患者人群。●本试验共入组398例受试者，其中PD-L1TPS1–49%占比为57.8%，PD-L1TPS≥50%占比为42.2%，与真实世界患者表达水平分布一致。●依沃西组总体安全性良好，无新的安全性信号。●AK112–303(HARMONi-2)临床研究详细数据将在即将举行的全球学术会议上公布。在真实世界中，约50%以上的NSCLC患者为PD-L1TPS≥1%的患者，本次临床结果强有力地证明了依沃西在一线治疗NSCLC的优异且广泛的临床价值。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2439602814"}